Humulin N (Nph) Cartridge (Insulin Human (Rdna))

Humulin N is prescribed to manage blood glucose levels in diabetes mellitus. It is used as part of a comprehensive diabetes treatment plan that may include diet, exercise, and other medications.

• Long‑acting basal insulin for Type 1 diabetes mellitus.
• Long‑acting basal insulin for Type 2 diabetes mellitus.
• Supplemental insulin therapy when rapid‑acting insulin is insufficient.
• Combination therapy with mealtime insulin analogues.
• Adjusted dosing for patients requiring stable overnight glucose control.

• Insulin human binds to insulin receptors on cell membranes, activating the intrinsic tyrosine kinase activity of the receptor. This triggers downstream signaling pathways that promote translocation of glucose transporter‑4 (GLUT‑4) to the cell surface, enhancing glucose uptake in muscle and adipose tissue, stimulating glycogen synthesis in the liver, and suppressing hepatic gluconeogenesis, thereby lowering plasma glucose concentrations.

Adverse reactions to Humulin N may vary in frequency and severity.

Common

• Injection site pain or erythema.
• Hypoglycemia (low blood glucose).
• Lipodystrophy at injection sites.
• Weight gain.
• Edema or fluid retention.

Serious

• Severe hypoglycemia leading to loss of consciousness.
• Allergic reactions such as urticaria, angioedema, or anaphylaxis.
• Persistent hyperglycemia indicating possible insulin resistance.
• Rare cases of insulin antibody formation.

Before starting Humulin N, patients should be evaluated for factors that may affect insulin therapy.

• Review history of hypoglycemia unawareness or severe episodes.
• Assess renal or hepatic impairment, which may alter insulin clearance.
• Monitor during pregnancy or lactation; adjust dosing as needed.
• Caution in patients with cardiovascular disease due to potential fluid shifts.
• Educate on proper injection technique to reduce lipodystrophy.
• Ensure regular blood glucose monitoring to avoid over‑correction.

Certain drugs can modify the glucose‑lowering effect of Humulin N.

Avoid

• Concurrent use of other insulin products without dose adjustment.
• High‑dose sulfonylureas that may precipitate severe hypoglycemia.
• Beta‑blockers masking hypoglycemia symptoms.

Use with caution

• Oral antihyperglycemics (e.g., metformin, thiazolidinediones) requiring dose titration.
• Corticosteroids that increase glucose levels.
• Diuretics that may affect fluid balance and insulin absorption.
• ACE inhibitors or ARBs, which can potentiate hypoglycemia in some patients.